

## The Seroprevalence of SARS-CoV-2 in Europe: A Systematic Review

Natasha Marcella Vaselli<sup>1\*</sup> (ORCID ID: 0000-0003-0220-9249), Daniel Hungerford (ORCID ID: 0000-0002-9770-0163 )<sup>1,2,3</sup>, Ben Shenton<sup>1</sup>, Arwa Khashkhusha<sup>4</sup> (Orchid ID= 0000-0002-7407-840), Nigel A. Cunliffe<sup>1,2</sup>, Neil. French<sup>1,3</sup>

### Affiliations

1. Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK
2. NIHR HPRU in Gastrointestinal Infections at the University of Liverpool, Liverpool, UK
3. NIHR HPRU in Emerging and Zoonotic Infections at the University of Liverpool, Liverpool, UK
4. School of Medicine, Faculty of Life Sciences, University of Liverpool, Liverpool, UK

### Word Count

**Abstract:** 250 (max 250)

**Full Text:** 3738 (max 4000)

**Number of figures/ tables:** 7

**Funding:** None

**Conflicts of Interest:** No conflicts of interest were declared by the authors.

**\*Correspondence:** N.Vaselli@liverpool.ac.uk

**Keywords:** COVID-19; SARS-CoV-2; serology; antibody; seroprevalence; immunity

## **Abstract**

### Background

A year following the onset of the COVID-19 pandemic, new infections and deaths continue to increase in Europe. Serological studies, through providing evidence of past infection, can aid understanding of the population dynamics of SARS-CoV-2 infection.

### Objectives

This systematic review of SARS-CoV-2 seroprevalence studies in Europe was undertaken to inform public health strategies including vaccination, that aim to accelerate population immunity.

### Methods

We searched the databases Web of Science, MEDLINE, EMBASE, SCOPUS, Cochrane Database of Systematic Reviews and grey literature sources for studies reporting seroprevalence of SARS-CoV-2 antibodies in Europe published between 01/12/2019 - 30/09/20. We provide a narrative synthesis of included studies. Studies were categorized into subgroups including healthcare workers (HCWs), community, outbreaks, pregnancy and children/school. Due to heterogeneity in other subgroups, we only performed a random effects meta-analysis of the seroprevalence amongst HCWs stratified by their country.

### Results

109 studies were included spanning 17 European countries, that estimated the seroprevalence of SAR-CoV2 from samples obtained between November 2019 – August 2020. A total of 53/109 studies included HCWs with a reported seroprevalence among HCWs ranging from 0.7% to 45.3%, which did not differ significantly by country. In community studies significant heterogeneity was reported in the seroprevalence among different age groups and the majority of studies reported there was no significant difference by gender.

### Conclusion

This review demonstrates a wide heterogeneity in reported seroprevalence of SARS-CoV-2 antibodies between populations. Continued evaluation of seroprevalence is required to understand the impact of public health measures and inform interventions including vaccination programmes.

## Introduction

On 11<sup>th</sup> March 2020 the World Health Organization (WHO) declared the spread of novel SARS-CoV-2 as a pandemic (1). SARS-CoV2 is thought to spread mainly by respiratory droplets, while some evidence also suggests spread via fomites and aerosols (2–4). SARS-CoV2 causes varying degrees of illness from mild symptoms including fatigue and myalgia to acute respiratory failure and death (5). As the pandemic unfolded evidence emerged that a large number of individuals are asymptomatic with SARS-CoV2 infection (6,7).

In order to control the spread of SARS-CoV-2 it is important to understand the extent to which different populations have already been exposed to the virus, especially as a large number of infections are asymptomatic. Many countries, organizational bodies and facilities have turned to mass testing to estimate the spread of infection and inform public health measures (8,9). One such testing strategy is by nasal and throat swabbing to detect viral RNA which has recently been piloted in England (10). A further method is mass testing of the population for antibodies against SARS-CoV-2 (11). Several tests for IgG, IgA and IgM antibodies against SARS-CoV2 have recently been developed. These broadly include enzyme linked immunosorbent assays, chemiluminescence immunoassays (CLIA) and point of care lateral flow assays (12).

Seroprevalence studies have been used in the past to help with outbreak responses. During a recent Ebola outbreak, seroprevalence studies were performed to gain further information on the immune response and immune protection (13). Seroprevalence studies have also been used for infections such rubella, mumps and measles to map resurgence and to gain further information on how public health strategies can target high risk populations

(14). Moreover, seroprevalence studies provide valuable information on vaccination strategies to achieve herd immunity.

By estimating the seroprevalence in different populations we can use the results to understand transmission dynamics, herd immunity and the immune response over time. These studies can help to guide the public health response to ultimately help prevent the spread of SARS-CoV2. Here we present the results of a systematic review on the seroprevalence of SARS-CoV2 in Europe.

## Methods

### Search strategy and selection criteria

This systematic review and meta-analysis adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was registered on the University of York database for Prospectively Registered Systematic Reviews (PROSPERO: 2020 CRD42020212149). We systematically searched electronic data sources from (01/12/2019) until (30/09/20) using search terms on seroprevalence and SARS-CoV-2. We searched the following electronic databases: Web of Science, MEDLINE, EMBASE, SCOPUS and Cochrane Database of Systematic Reviews. We also searched database search engine EBSCO to search the following databases EBSCOhost e-book collection, biomedical reference collection, CINAHL plus and MEDLINE Complete. We conducted a secondary search by searching the reference lists of included studies for relevant articles.

Furthermore, we searched the grey literature. Firstly, we searched pre-print articles in the electronic database search engine EPMC to search pre-print databases including MedRXIV

and BioRXIV. Secondly, we then used the database OpenGrey to search research reports, doctoral dissertations, conference papers and other forms of grey literature. Thirdly we searched the websites of national and international health agencies for reports relating to the seroprevalence of SARS-CoV-2 (World Health Organization, European Centres for Disease Control, Public Health England, Department of Health and Social Care in UK). Finally, we conducted a google search for further government reports.

Search terms were developed alongside a health science librarian.

Search Strategy	
1	COVID-19 OR SARS CoV-2
2	antibod* OR immun*
3	Seroprevalence
4	1 AND 2 AND 3
5	animals NOT humans
6	4 NOT 5

Studies were included if they were written in English and published between 1/12/19-30/09/20 and were cross-sectional or cohort studies. Vaccine evaluations and randomised controlled trials were excluded.

### Data extraction

Titles and abstracts of retrieved studies were de-duplicated and screened independently by two reviewers to identify if they met the inclusion criteria. Screened references then underwent full text review by two reviewers independently. Any disagreement between them over the eligibility of studies was resolved through discussion with third reviewer.

A standardised data extraction form was used. Data were extracted on the characteristics of the study (country, date, setting, selection method, funder), antibody assay employed,

specificity and sensitivity of the assay, sample characteristics (age, gender, ethnicity, comorbidities) and prevalence. Data extraction was carried out autonomously by the reviewers and consensus was sought between the team.

#### Assessment of the methodological quality of included studies

We assessed the risk of bias using an adapted version of the Hoy et al modified Risk of Bias Tool, as used by Nguyen et al (15). This is a tool designed to assess the risk of bias in population-based prevalence studies. It uses a scoring system to assess the external and internal validity of the study. Studies that score 0-3 points are classified as low risk, 4-6 high risk and 7- 9 high risk. Two reviewers independently applied the criteria. Disagreements were resolved through discussion.

#### Data Analysis

We provided a narrative synthesis of the findings of all included studies, study population characteristics, antibody assays used and seroprevalence estimates for each study. Studies were categorized into subgroups including those that examined health care workers (HCWs), community studies, outbreaks, seroprevalence in children/ schools and seroprevalence studies performed in pregnant women. We used Metaprop in STATA version 14, statistical software (Stata Corp. College Station, TX, USA), package to perform a random-effects meta-analysis of seroprevalence amongst health care workers (HCWs) stratified by country. We also performed a random – effects meta-analysis of seroprevalence amongst health care workers (HCWs) stratified by their risk of exposure to SARS-CoV-2 infected patients. HCWs were categorised as high risk if they worked with patients with known SARS-CoV-2 infection, medium risk if they had patient contact but without known SARS-CoV-2

infection and low risk if they had no patient contact (e.g., laboratory staff and administrative staff). If studies included participants from a mixture of risk groups they were categorised as medium risk. Heterogeneity was measured using the  $I^2$  statistic which describes the percentage of total variation due to inter-study heterogeneity. Tests of heterogeneity were undertaken within the sub-groups and for the overall meta-analysis. Sensitivity analysis was done by removing those studies with a moderate risk of bias score. This had no effect of the  $I^2$  value, so these studies were included in the final meta-analysis.

After reviewing the relevant literature, we did not perform traditional asymmetry tests and funnel plots for assessing publication bias, as the meta-analysis we conducted was a summary of proportions and not a comparison of treatments/interventions (16,17).

## **Role of the Funder**

This study received no external funding. Staff were supported through National Institute of Health Research (NIHR) awards and the NIHR had no role in the concept, design, analysis and interpretation of the data.

## **Results**

The literature search yielded 1648 articles. After removing duplicates and excluding studies based on their abstract or through full text examination 109 studies were identified as eligible (Figure 1). The 109 articles spanned 17 countries in Europe and estimated the seroprevalence of SAR-CoV2 from serum samples dated from November 2019 – August 2020. The 109 articles reviewed the seroprevalence in approximately 500,000 samples; 59.7% of samples belonged to females and had an overall age range of 0 – 90+ years. Data

were recorded on the type of funding the studies received; this included government funding, research grants and some studies received no external funding (table 1).

**Figure 1: PRIMSA Flow chart**

**Table 1: Included studies, dates of sampling, population studied and overall seroprevalence**

Country	Author, year	Time period	Population	Total Seroprevalence (95% CI)
Austria	Orth-Höller et al 2020(18)	20th-27th March	Primary and Secondary care physicians in Tyrol	5% (3.3-7.7)
	Knabl et al 2020(19)	April 21st- April 27th	Residents in Ischgl/Tyrol	42.4% (39.8-44.7)
	Fuereder et al 2020 (20)	21st March - 4th June	HCWs and patients the Division of Oncology, Medical University of Vienna, Austria, during the COVID-19 pandemic between 1 April and 4 June 2020.	HCWs - 3.2% (0.4-11.2%) and patients 2.4% (0.3-8.3%)
	Reiter et al 2020(21)	Not recorded but published on medRxiv in July	Staff members of the Division of Nephrology and Dialysis, Department of Medicine III, at the Medical University of Vienna, Austria.	25.5% (20.4-31.5)
Belgium	Herzog et al 2020(22)	30th March - 5th July	Residual sera from ten private diagnostic laboratories in Belgium.	30 March – 5 April 2.90% (2.3-3.4%). 20 – 26 April 6% (5.1-7.1%). 18 – 25 May 6.9% (5.9-8). 8 – 13 June 5.5% (4.7-6.5%). 29 June – 4 July 4.5% (3.7-5.4%)
	Berardis et al 2020(23)	16th April 16 and 19th May	Cystic Fibrosis patients followed in the CF reference centre of the Cliniques universitaires Saint-Luc (Brussels).	2.70%
	Steensels et al 2020(24)	22nd April - 30th April	HCWs at Hospital East-Limburg	6.40%
	Martin et al 2020(25)	15th April-18th May	HCWs on COVID wards in Centre Hospitalier Universitaire Saint-Pierre (CHU Saint-Pierre) in Brussels	11-12%
	Desombere et al (26)	6th - 10th May	HCWs in Belgium	8.40%
	Blairon et al 2020(27)	25th May 25 - 19th June	HCWs at network of Iris hospitals South (HIS-IZZ, Brussels, Belgium)	14.60%
	Jerković et al 2020(28)	23rd - 28th April	Factory employees living in the Split-Dalmatia and Šibenik-Knin County	1.27% (0.77-1.98%)

Croatia	Vilibic-Cavlek et al 2020(29)	25th April - 24th May	HCWs and allied professions	2.7% *based on IgG
	Iversen et al 2020 (30)	15th April and 23rd April	HCWS and blood donors in the Capital Region of Denmark	HCWS - 4.04% (3.82–4.27). Blood Donors 3.04% (2.58–3.57)
	Erikstrup et al 2020(31)	6th April to 3rd May	Blood Donors in Denmark	2% (1.8–2.2)
Denmark	Jespersen et al 2020(32)	May 18th until June 19th	HCWS and administrative staff that work in hospitals in the Central Denmark Region	3.7% (3.5%–4.0%)
	Laursen et al 2020(33)	22nd June to 10th August	Emergency and non-emergency HCWs employed by Falck in Sweden and Denmark	Denmark - 2.8%. Sweden 8.3%
	Petersen et al 2020(34)	27th April – 1st May	Residents of the Faroe Islands	0.6% (0.2%–1.2%)
	Germain et al 2020(35)	1st November 2019 to 16th March 2020	All tissue donors at Lille Tissue bank	1.70%
	Solodky et al 2020(36)	1st March - 16th April	HCWs and cancer patients	HCWs 5.4%. Cancer patients 5.9%
	Grzelak et al 2020(37)	20th March	A cohort of pauci-symptomatic individuals in Crepy-en-Valois. Blood donors from the Etablissement Français du Sang (EFS) in Lille (France)	Blood donors mean of 3%. Pauci symptomatic cohort mean of 32%.
	Carrat et al 2020(38)	1st April - 27th May	Residents from Ile-de-France (IDF) or Grand Est (GE) or Nouvelle-Aquitaine (NA)	6.70%
France	Gallian et al 2020(39)	Last week of March to the first week of April	Blood Donors	2.70%
	Sermet et al 2020(40)	1st April - 1st June	Non COVID paediatric patients consulting or hospitalized in a paediatric tertiary health care department of the Assistance Publique-Hôpitaux de Paris	22.19%
	Fontanet et al 2020(41)	28th - 30th April	Pupils, their parents and relatives, and staff of primary schools exposed to SARS-CoV-2 in February and March 2020 in a city north of Paris, France	10.40%
	Mattern et al 2020(42)	4th May - 31st May	Patients admitted to the delivery room at Antoine Béclère Hospital maternity ward (Paris area, France)	8.00%
	Péré et al 2020(43)	2nd May - 26th June	HCWS at Hôpital Européen Georges Pompidou	12.20%

	Simon et al 2020(44)	February - April 2020	Patients with IMIDs with and without continuous cytokine blockade. HCWs and a cohort of healthy participants unrelated to health care	Healthy participants 2.27% HCWs 4.2%. IMIDs on cytokine inhibition 0.75%. IMIDs not on cytokine inhibition 3.08%
	Fischer et al 2020(45)	9th March - 3rd June	Blood donors in three German federal states North Rhine-Westphalia, Lower Saxony and Hesse	0.91% (0.58–1.24%)
	Brandstetter et al 2020(46)	20th March	HCWs at university children's and maternity hospital in Regensburg	16.90%
	Brehm et al 2020(47)	20th March - 24th July	Employees of University Medical Center Hamburg-Eppendorf	1.8% (1-2.5%)
	Behrens et al 2020(48)	23rd March - 17th April	HCWs involved in COVID-19 patient care	0.90%
	Korth et al 2020(49)	25th March - 21st April	HCWS at University Hospital Essen	1.60%
	Streeck et al 2020(50)	31st March - 6th April	Residents of Gangelt	13.6% * based on IgG
Germany	Krähling et al 2020(51)	6th April - 14th April	Employees of Infraserv Höchst, a large industrial site operator in Frankfurt am Main	0.50%
	Schmidt et al 2020(52)	20th April - 30th April	Employees BDH-Clinic Hessisch Oldendorf	2.86%
	Aziz et al 2020(53)	24th April - 30th June	Individuals enrolled in the Rhineland Study an ongoing community-based prospective cohort study in people aged 30 years and above in the city of Bonn, Germany. Group I all living participants who had been enrolled in the Rhineland Study until March 18, 2020. Group II individuals who were eligible for but had not yet participated in the Rhineland Study.	Group I: 0.97% (0.72-1.30). Group II: 1.94% (0.84-4.42)
	Weis et al 2020(54)	12th May - 22nd May	Residents in Neustadtam Rennsteig	8.40%
	Armann et al 2020(55)	25th May - 30th June	Students grade 8–11 and their teachers in 13 secondary schools in eastern Saxony	0.60%
	Epstude et al 2020(56)	15th June - 30th June	HCWs and housekeeping staff in an oncology unit	3.10%
	Hoffmann et al 2020(57)	20th July	HCWs in a standard care hospital in Oberspreewald-Lausitz	1.30%

	Bogogiannidou et al 2020(58)	March and April	Individuals who visited the laboratories for a check-up, chronic disease follow-up or other reasons unrelated to COVID-19 in the whole of Greece	March: 0.24% (0.03-0.45%). April 0.42% (0.23-0.61%)
Greece	Psichogiou et al 2020(59)	30th April - 15th May	HCWS across two hospitals in Greece	1.00%
	Tsitsilonis et al 2020(60)	June-July 2020	Student and staff at National and Kapodistrian University of Athens	1.00%
Iceland	Gudbjartsson et al 2020(61)	January - July	Two groups of qPCR-positive Icelanders and six groups of Icelanders who had not been qPCR-tested or who had been tested and had received a negative result	4.22%
	Plebani et al 2020(62)	22nd February - 29th May	HCWs in several Structures of the National Healthcare Service of the Veneto Region	4.6% (4.1-5.0%)
	Valenti et al 2020(63)	24th February - 8th April	Blood donors in Milan	5.07%
	Pancrazi et al 2020(64)	17th - 21st March	Patients in the Emergency Room and from subjects undergoing health surveillance by territorial and hospital prevention departments in Tuscany	13.00%
	Vena et al 2020 (65)	March and April	Residents living in Liguria and Lombardi regions	11.00%
	Norsa et al 2020(66)	March- July	Patients with IBD on biologic treatment	21.10%
	Percivalle et al 2020(67)	18th March - 6th April	Registered blood donors in Lodi Italy	23.00%
	Lahner et al 2020(68)	18th March- 27th April	HCWS in a teaching hospital in Rome	0.70%
	Fusco et al 2020(69)	23rd March - 2nd April	HCWs working in a specialist infectious disease setting, the 'D. Cotugno' hospital in Naples, Italy.	1.70%
	Sotgiu et al 2020(70)	2nd - 16th April	HCWs at San Paulo University General Hospital	7.4% * based on IgG
	Amendola et al 2020(71)	15th April	HCWs in Buzzi Hospital	5.13%
Italy	Carozzi et al 2020 (72)	20th April	HCWs at AOUS in Siena, AOUC in Florence, AOUP in Pisa, and AOUM, the Meyer Hospital	2.4% * only including positive results and not doubtful

	Comar et al 2020(73)	Published in medRxiv in April	All employees of the Mother and Child Research Hospital IRCCS-Burlo Garofolo	7.2% * just including positive and not borderline results.
	Cosma et al 2020(74)	16th April - 4th June	Pregnant women attending for first trimester screening (11-13 weeks of gestation) at Sant'Anna Hospital, Turin, Piedmon	10.10%
	Sandri et al 2020(75)	28th April - 16th May	Employees of 7 different hospitals, located across the Lombardy region	11.21%
	Fiore et al 2020(76)	1st May - 31st May	Blood donors in Apulia region, South Eastern Italy	0.99%
	Pagani et al 2020(77)	18th May - 7th June	Residents of Castiglione D'Adda	22.6% (17.2-29.1%)
	Paderno et al 2020(78)	No date recorded	All staff working in a COVID-19-free Otolaryngology Department in Italy	6.90%
	Tosato et al 2020(79)	Not recorded but published on medRxiv in May	HCWs working in the Department of Laboratory Medicine	4.50%
Netherlands	Westerhuis et al 2020(80)	2nd March - 3rd April	Patients of the Erasmus Medical Centre in Rotterdam	March: 0.7%. April: 3%
	Slot et al 2020(81)	1st - 15th April	Plasma donations	2.60%
Luxembourg	Snoeck et al 2020(82)	15th April - 5th May	Population of Luxembourg	1.97%
Portugal	Figueiredo-Campos et al 2020(83)	6th April - 10th July	Hospitalised patients and HCWs who tested positive for SARS-CoV-2 by PCR, healthy post-COVID19 volunteers and staff of the University of Lisbon	Patients: 51%, HCWs 100%, plasma donations 88%, University staff 1.5%
	Dacosta-Urbia et al 2020(84)	March - April	HCWs of the Paediatric Department of the Hospital Clínico Universitario de Santiago de Compostela	4.00%
	Garcia-Basteiro et al 2020(85)	28th March - 9th April	HCWs at Hospital Clínic of Barcelona	9.3% (7.1-12%)
	Valdivia et al 2020(86)	13th - 30th April	HCWs at Hospital Clínico Universitario of Valencia	3.50%
	Galán et al 2020(87)	14th -27th April	All HCWS Hospital Universitario Fundación Alcorcón	31.60%
	Crovatto et al 2020(88)	14th April-5th May	Pregnant women consecutively attending first trimester screening or delivery	14.30%
	Garralda Fernandez et al 2020(89)	14th April - 13th May	HCWs at Hospital Universitario de Fuenlabrada.	16.9% * based on IgG

Spain	Olalla et al 2020(90)	15th - 25th April	HCWs of the Costa del Sol Hospital in Marbella of the units involved in patient care with CoVID-19	2.20%
	Martín et al 2020(91)	20th April	General practitioners (GP) and primary care nurses in the Healthcare Area of León, who worked in health centres or nursing homes.	5.90%
	Montenegro et al 2020(92)	21 April to 24 April 2020 (Study population A) and from 29 April to 5 May 2020 (Study population B)	Population A: individuals registered in a primary health care centre, from a community area of Barcelona, Spain. Population B: Patients from GPs in Barcelona presenting with mild-moderate symptoms of COVID but no diagnosis of COVID	Population A: 5.47% (3.44–8.58%). Population B: 38.49% (34.78%–42.33%)
	Moncunill et al 2020(93)	April - May	HCW from Hospital Clínic de Barcelona	14.50%
	Soriano et al 2020(94)	April - May	Asymptomatic adults in Madrid	13.80%
	Pollan et al 2020(95)	27th April - 11th May	Spanish households	5% (4.7-5.4%) * based on POC testing
	Barallat et al 2020(96)	4th - 22nd May	HCWS of the ICS-Northern Metropolitan Area of Barcelona	10.30%
	Cabezón-Gutiérrez et al 2020(97)	1st- 19th June	Oncology outpatients who attended the medical oncology consultation of the University Hospital of Torrejón	31.40%
	Castro Dopico et al 2020(98)	30th March - 23rd August	Blood Donors and pregnant women in Stockholm	13.7% (9.5-19.3%) * estimated by ENS Learner
	Rudberg et al 2020(99)	24th April - 8th May	HCWs at Danderyd Hospital	19.10%
	Lindahl et al 2020(100)	20th April	Employees of elderly care homes situated in Stockholm city and its suburbs	23% (20.4–25.7%)
Sweden	Roxhed et al 2020(101)	20th April	Households in Stockholm	4.4% (2.4%-6.3%) * for IgG
	Lundkvist et al 2020(102)	17th-18th June	Residents of Norra Djurgårdsstaden and Tensta in Stockholm	15.00%
	Laursen et al 2020(33)	22nd June to 10th August	Emergency and nonemergency HCWs employed by Falck in Sweden and Denmark	Denmark - 2.8%. Sweden 8.3%
	Emmenegger et al 2020(103)	February - July	Patients entering the University Hospital of Zurich and healthy blood donors in Zurich	Hospitalised patients: March 2020 0.3% (0.1% - 0.5%). April 2020 1.4% (1.0%-1.7%). Blood donors: April 1.2% (0.7%-1.8%). May 1.6% (1.0%-2.3%) *

					estimated by quadratic discriminant analysis
Switzerland	Stringhini et al 2020(104)	6th April - 9th May	Residents from the Canton of Geneva		7.90%
	Ulyte et al 2020(105)	June-July	Schools in the Canton of Zurich		2.8% (1.4-6.1%)
Turkey	Alkurt et al 2020(106)	30th May - 6th June	HCWs in the University of Health Sciences Umraniye Teaching and Research Hospital (UEAH), Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Hospital (Cerrahpasa), Darica Farabi Teaching and Research Hospital (Farabi)		12.30%
	Thompson et al 2020(107)	17th March - 19th May 2020	Blood donors in Scotland		3.17%
	Houlihan et al 2020(108)	26th March - 8th April	HCWs at UCLH who work in A&E, COVID ward, AMU, ICU or haematology		45.30%
	Pallett et al 2020(109)	8th April - 12th June	HCWS in two hospitals in London		39.30%
	Waterfield et al 2020(110)	16th April - 3rd July	Children of healthcare workers, aged between 2 and 15 years		6.90%
	Eyre et al 2020(111)	23rd April - 8th June	Hospital staff at Oxford University Hospitals NHS Foundation Trust		10.70%
	Shields et al 2020(112)	24th -25th April	HCWs at University of Birmingham and University Hospitals Birmingham NHS Foundation Trust		24.40%
UK	Clarke et al 2020(113)	27th April - 7th May	Patients receiving ICHD within two units affiliated with Imperial College Renal and Transplant Centre		36.20%
	Wells et al 2020(114)	27th April - 2nd June	Participants of the Twins UK Cohort Study		12.00%
	The Government of Jersey 2020(115)	29th April - 5th May	Residents in Jersey over 16 years of age		3.1% (+/- 1.3%)
	Poulikakos et al 2020(116)	4th-6th May	HCWs from renal and biochemistry department in a tertiary hospital in the north west of England		6.00%
	Khalil et al 2020(117)	15th - 28th May	HCWS at Portland Hospital for Women and Children		22.00%
	Grant et al 2020(118)	15th May - 5th June	HCWs at Whittington Health		31.64%
	Ladhani et al 2020(119)	20th May	Residents and staff of the six care homes following an outbreak of COVID-19		77.9% (73.6-81.7%)
	Biobank 2020(120)	27th May - 14th August	UK Biobank participants		8.2% (7.9%-8.7%)
	Public Health England 2020(121)	May	Healthy adult blood donors, supplied by the NHS Blood and Transplant (NHS BT)		8.5% (6.9-10%) * this is adjusted

	Mulchandani et al 2020 (122)	1st June - 26th June	Police and Fire and Rescue services, healthcare workers and healthcare workers with previously positive for SARS-CoV2	Police and Fire and Rescue services: 10.6%. HCWs: 23.3%
	Nsn et al 2020(123)	20th June	Residents in 4 nursing homes in UK where a covid-19 outbreak happened	71.80%
	Favara et al 2020(124)	June - July	HCWs with direct patient contact working in an oncology unit in either of the following hospitals the Queen Elizabeth Hospital Kings Lynn NHS Foundation Trust (QEHS), North West Anglia NHS Foundation Trust (Peterborough City Hospital, NWA), and Cambridge University Hospitals NHS Foundation Trust (CUH).	13.3% * using Luminex assay on day 28
	Ladhani et al 2020(125)	June - July	Teachers and students in 131 schools across England	11.7% (10.5-13.3%)
	Ward et al 2020 (126)	20th June - 13th July	Residents in England over the age of 18 years	6% (5.8-6.1%) * adjusted for test performance and re-weighted for sampling

### Assessment of the methodological quality of included studies

Each study underwent a risk of bias assessment using the modified Hoy et al risk of bias tool

(15). Twenty eight of the 109 studies were deemed to be at moderate risk of bias

(26,29,36,40,46,48,49,58,60,64,65,79,86,88,91,97,98,101,105,107,110,111,114,116,117,121

,123,125). This was often due to lack of information about the sampling frame, selection

process and non-response bias. No studies scored high risk (Table 2).

**Table 2: Assessment of the methodological quality of included studies**

Country	Author, year	Overall Risk of Study: high, moderate or low	Reason if moderate/high risk
	Orth-Höller et al 2020(18)	Low risk	
	Knabl et al 2020(19)	Low risk	

Austria	Fuereder et al 2020 (20)	Low risk
	Reiter et al 2020(21)	Low risk
	Herzog et al 2020(22)	Low risk
Belgium	Berardis et al 2020(23)	Low risk
	Steensels et al 2020(24)	Low risk
	Martin et al 2020(25)	Low risk
Croatia	Desombere et al (26)	Moderate risk Not enough information given about the sampling frame, definition of a positive result, selection process, type of test used, if the same test was used on all participants and non-response bias.
	Blairon et al 2020(27)	Low risk
	Jerković et al 2020(28)	Low risk
Denmark	Vilibic-Cavlek et al 2020(29)	Moderate risk Not enough information given about the sampling frame, selection process and non- response bias.
	Iversen et al 2020 (30)	Low risk
	Erikstrup et al 2020(31)	Low risk
Denmark	Jespersen et al 2020(32)	Low risk
	Laursen et al 2020(33)	Low risk
	Petersen et al 2020(34)	Low risk

Germain et al 2020(35)	Low risk	
	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Solodky et al 2020(36)		
Grzelak et al 2020(37)	Low risk	
Carrat et al 2020(38)		
France	Low risk	
	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Gallian et al 2020(39)		
Sermet et al 2020(40)		
Fontanet et al 2020(41)		
Mattern et al 2020(42)		
Péré et al 2020(43)		Low risk
Simon et al 2020(44)		
Fischer et al 2020(45)		
Brandstetter et al 2020(46)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.

Low risk		
Brehm et al 2020(47)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Behrens et al 2020(48)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Korth et al 2020(49)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Streeck et al 2020(50)	Low risk	
Germany	Low risk	
Krähling et al 2020(51)	Low risk	
Schmidt et al 2020(52)	Low risk	
Low risk		
Aziz et al 2020(53)	Low risk	
Weis et al 2020(54)	Low risk	
Armann et al 2020(55)	Low risk	
	Low risk	
Epstude et al 2020(56)	Low risk	
Hoffmann et al 2020(57)	Low risk	
	Moderate risk	Not enough information given about definition of a positive result, non-responder bias and discrepancies in the tables.
Greece	Bogogiannidou et al 2020(58)	
	Psichogiou et al 2020(59)	Low risk
Tsitsilonis et al 2020(60)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
	Low risk	
Iceland	Gudbjartsson et al 2020(61)	

		Low risk
	Plebani et al 2020(62)	
	Valenti et al 2020(63)	Low risk
	Pancrazi et al 2020(64)	Moderate risk Not enough information given about the sampling frame, selection process and non- response bias.
	Vena et al 2020 (65)	Moderate risk Not enough information given about the sampling frame, selection process and non- response bias.
	Norsa et al 2020(66)	Low risk
	Percivalle et al 2020(67)	Low risk
	Lahner et al 2020(68)	Low risk
	Fusco et al 2020(69)	Low risk
	Sotgiu et al 2020(70)	Low risk
	Amendola et al 2020(71)	Low risk
Italy	Carozzi et al 2020 (72)	Low risk
	Comar et al 2020(73)	Low risk
	Cosma et al 2020(74)	Low risk
	Sandri et al 2020(75)	Low risk
	Fiore et al 2020(76)	Low risk
	Pagani et al 2020(77)	Low risk
	Paderno et al 2020(78)	Low risk
	Tosato et al 2020(79)	Moderate risk Not enough information given about the sampling frame, selection process and non- response bias.

Netherlands	Westerhuis et al 2020(80)	Low risk
	Slot et al 2020(81)	Low risk
Luxembourg	Snoeck et al 2020(82)	Low risk
		Low risk
Portugal	Figueiredo-Campos et al 2020(83)	
	Dacosta-Urbieto et al 2020(84)	Low risk
Spain	Garcia-Basteiro et al 2020(85)	Low risk
	Valdivia et al 2020(86)	Moderate risk Not enough information given about the sampling frame, selection process and non- response bias.
Spain	Galán et al 2020(87)	Low risk
	Crovetto et al 2020(88)	Moderate risk Not enough information given about the sampling frame, selection process and non- response bias.
Spain	Garralda Fernandez et al 2020(89)	Low risk
	Olalla et al 2020(90)	Low risk
Spain	Martín et al 2020(91)	Moderate risk High nonresponse rate and not enough information given about the sampling frame and selection process.
	Montenegro et al 2020(92)	Low risk
Spain	Moncunill et al 2020(93)	Low risk
	Soriano et al 2020(94)	Low risk

		Low risk	
	Pollan et al 2020(95)		
	Barallat et al 2020(96)	Low risk	
	Cabezón-Gutiérrez et al 2020(97)	Moderate risk	Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias.
	Castro Dopico et al 2020(98)	Moderate risk	Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias.
	Rudberg et al 2020(99)	Low risk	
Sweden	Lindahl et al 2020(100)	Low risk	
	Roxhed et al 2020(101)	Moderate risk	Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias.
	Lundkvist et al 2020(102)	Low risk	
	Laursen et al 2020(33)	Low risk	
Switzerland	Emmenegger et al 2020(103)	Low risk	
	Stringhini et al 2020(104)	Low risk	
	Ulyte et al 2020(105)	Moderate risk	Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias.
Turkey	Alkurt et al 2020(106)	Low risk	
	Thompson et al 2020(107)	Moderate risk	Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias.

		Low risk
Houlihan et al 2020(108)		
Pallett et al 2020(109)	Low risk	
Waterfield et al 2020(110)	Moderate risk	Not enough information given about the sampling frame, definition of a positive result, selection process and non-response bias.
Eyre et al 2020(111)	Moderate risk	High nonresponse rate and not enough information given if the same test was used on all participants and definition of a positive result
Shields et al 2020(112)	Low risk	
Clarke et al 2020(113)	Low risk	
Wells et al 2020(114)	Moderate risk	High nonresponse rate and not enough information given about the sampling frame and selection process.
The Government of Jersey 2020(115)	Low risk	
Poulikakos et al 2020(116)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Khalil et al 2020(117)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Grant et al 2020(118)	Low risk	
Ladhani et al 2020(119)	Low risk	
Biobank 2020(120)	Low risk	
Public Health England 2020(121)	Moderate risk	Not enough information given about the sampling frame, selection process and non-response bias.
Mulchandani et al 2020 (122)	Low risk	
Nsn et al 2020(123)	Moderate risk	Not enough information given about the selection process and non-response bias.
Favara et al 2020(124)	Low risk	

Ladhani et al 2020(125)	Low risk	
Ward et al 2020 (126)	Low risk	
		<b>Health Care</b>

## Workers

53 studies included seroprevalence data among HCWs. These studies included data from 13 countries in Europe and were conducted between February 2020 and August 2020 (Table 3).

**Table 3: Studies reporting the seroprevalence among HCWs, dates the studies were conducted, population studied and the overall seroprevalence**

Country	Author, year	Time period	Population	Total Seroprevalence (95% CI)
Austria	Orth-Höller et al 2020(18)	20th-27th March	Primary and Secondary care physicians in Tyrol	5% (3.3-7.7)
	Fuereder et al 2020(20)	21st March -4th June	HCWS and patients the Division of Oncology, Medical University of Vienna, Austria, during the COVID-19 pandemic between 1 April and 4 June 2020.	HCWs - 3.2% (0.4-11.2%) and patients 2.4% (0.3-8.3%)
	Reiter et al 2020(21)	Not recorded but published on medRxiv in July	Staff members of the Division of Nephrology and Dialysis, Department of Medicine III, at the Medical University of Vienna, Austria.	25.5% (20.4-31.5)
	Stensels et al 2020(24)	22nd April - 30th April	HCWs at Hospital East-Limburg	6.40%
	Martin et al 2020(25)	15th April- 18th May	HCWS on COVID wards in Centre Hospitalier Universitaire Saint-Pierre (CHU Saint-Pierre) in Brussels	11-12%
Belgium	Desomber et al(26)	6th - 10th May	HCWs in Belgium	8.40%
	Blairon et al 2020(27)	25th May 25 - 19th June	HCWS at network of Iris hospitals South (HIS-IZZ, Brussels, Belgium)	14.60%
Croatia	Vilibic-Cavlek et al 2020(29)	25th April - 24th May	HCWs and allied professions	2.7% *based on IgG

	Iversen et al 2020 (30)	15th April and 23rd April	HCWS and blood donors in the Capital Region of Denmark	HCWS - 4.04% (3.82-4.27). Blood Donors 3.04% (2.58-3.57)
Denmark	Jespersen et al 2020(32)	May 18th until June 19th	HCWS and administrative staff that work in hospitals in the Central Denmark Region	3.7% (3.5%-4.0%)
	Laursen et al 2020(33)	22nd June to 10th August	Emergency and non-emergency HCWs employed by Falck in Sweden and Denmark	Denmark - 2.8%. Sweden 8.3%
	Solodky et al 2020(36)	1st March - 16th April	HCWs and cancer patients	HCWs 5.4%. Cancer patients 5.9%
France	Péré et al 2020 (43)	2nd May - 26th June	HCWS at Hôpital Européen Georges Pompidou	12.20%
	Simon et al 2020(44)	February - April 2020	Patients with IMIDs with and without continuous cytokine blockade. HCWs and a cohort of healthy participants unrelated to health care	Healthy participants 2.27% HCWs 4.2%. IMIDs on cytokine inhibition 0.75%. IMIDs not on cytokine inhibition 3.08%
	Brandstetter et al 2020(46)	20th March	HCWs at university children's and maternity hospital in Regensburg	16.90%
	Behrens et al 2020(48)	23rd March - 17th April	HCWs involved in COVID-19 patient care	0.90%
Germany	Korth et al 2020(49)	25th March - 21st April	HCWS at University Hospital Essen	1.60%
	Schmidt et al 2020(52)	20th April - 30th April	Employees BDH-Clinic Hessisch Oldendorf	2.86%
	Epstude et al 2020(56)	15th June - 30th June	HCWs and housekeeping staff in an oncology unit	3.10%
	Hoffmann et al 2020(57)	20th July	Health care workers in a standard care hospital in Oberspreewald-Lausitz	1.30%
Greece	Psichogiou et al 2020(59)	30th April - 15th May	HCWS across two hospitals in Greece	1.00%
	Plebani et al 2020(62)	22nd February - 29th May	HCWs in several Structures of the National Healthcare Service of the Veneto Region	4.6% (4.1-5.0%)
	Lahner et al 2020(68)	18th March- 27th April	HCWS in a teaching hospital in Rome	0.70%
	Fusco et al 2020(69)	23rd March - 2nd April	HCWs working in a specialist infectious disease setting, the 'D. Cotugno' hospital in Naples, Italy.	1.70%
	Sotgiu et al 2020(70)	2nd - 16th April	HCWs at San Paulo University General Hospital	7.4% * based on IgG

	Amendola et al 2020(71)	15th April	HCWs in Buzzi Hospital	5.13%
Italy	Carozzi et al 2020(72)	20th April	HCWs at AOUS in Siena, AOUC in Florence, AOUP in Pisa, and AOUM, the Meyer Hospital	2.4% * only including positive results and not borderline results.
	Comar et al 2020(73)	Published in medRxiv in April	All employees of the Mother and Child Research Hospital IRCCS-Burlo Garofolo	7.2% * just including positive and not borderline results.
	Sandri et al 2020(75)	28th April - 16th May	Employees of 7 different hospitals, located across the Lombardy region	11.21%
	Paderno et al 2020 (78)	No date recorded	All staff working in a COVID-19-free Otolaryngology Department in Italy	6.90%
	Tosato et al 2020(79)	Not recorded but published on medRxiv in May	HCWs working in the Department of Laboratory Medicine	4.50%
Portugal	Figueiredo-Campos et al 2020(83)	6th April - 10th July	Hospitalised patients and HCWs who tested positive for SARS-CoV-2 by PCR, healthy post-COVID19 volunteers and staff of the University of Lisbon	Patients: 51%, HCWs 100%, plasma donations 88%, University staff 1.5%
	Dacosta-Urbieto et al 2020(84)	March - April	HCWs of the Paediatric Department of the Hospital Clínico Universitario de Santiago de Compostela	4.00%
	Garcia-Basteiro et al 2020(85)	28th March - 9th April	HCWs at Hospital Clínic of Barcelona	9.3% (7.1-12%)
	Valdivia et al 2020(86)	13th - 30th April	HCWs at Hospital Clínico Universitario of Valencia	3.50%
	Galán et al 2020(87)	14th -27th April	All HCWS Hospital Universitario Fundación Alcorcón	31.60%
	Garralda Fernandez et al 2020(89)	14th April - 13th May	HCWs at Hospital Universitario de Fuenlabrada.	16.9% * based on IgG
Spain	Olalla et al 2020(90)	15th - 25th April	HCWs of the Costa del Sol Hospital in Marbella of the units involved in patient care with CoVID-19	2.20%

	Martín et al 2020(91)	20th April	General practitioners (GP) and primary care nurses in the Healthcare Area of León, who worked in health centres or nursing homes.	5.90%
	Moncunill et al 2020 (93)	April - May	HCW from Hospital Clínic de Barcelona	14.50%
	Barallat et al 2020(96)	4th - 22nd May	Healthcare workers of the ICS-Northern Metropolitan Area of Barcelona	10.30%
	Rudberg et al 2020(99)	24th April - 8th May	HCWs at Danderyd Hospital	19.10%
Sweden	Roxhed et al 2020(101)	20th April	Households in Stockholm	4.4% (2.4%-6.3%) * for IgG
	Laursen et al 2020(33)	22nd June to 10th August	Emergency and non-emergency HCWs employed by Falck in Sweden and Denmark	Denmark - 2.8%. Sweden 8.3%
Turkey	Alkurt et al 2020(106)	30th May - 6th June	HCWs in the University of Health Sciences Umranije Teaching and Research Hospital (UEAH), Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Hospital (Cerrahpasa), Darica Farabi Teaching and Research Hospital (Farabi)	12.30%
	Houlihan et al 2020(108)	26th March - 8th April	HCWs at UCLH who work in A&E, COVID ward, AMU, ICU or haematology	45.30%
	Pallett et al 2020 (109)	8th April - 12th June	HCWS in two hospitals in London	39.30%
	Eyre et al 2020(111)	23rd April - 8th June	Hospital staff at Oxford University Hospitals NHS Foundation Trust	10.70%
	Shields et al 2020(112)	24th -25th April	HCWs at University of Birmingham and University Hospitals Birmingham NHS Foundation Trust	24.40%
UK	Poulikakos et al 2020(116)	4th-6th May	HCWs from renal and biochemistry department in a tertiary hospital in the north west of England	6.00%
	Khalil et al 2020(117)	15th - 28th May	HCWS at Portland Hospital for Women and Children	22.00%
	Grant et al 2020(118)	15th May - 5th June	HCWs at Whittington Health	31.64%
	Mulchandani et al 2020(122)	1st June - 26th June	Police and Fire and Rescue services, healthcare workers and healthcare workers with previously positive for SARS-	Police and Fire and Rescue services: 10.6%. HCWs: 23.3%

CoV2			
Favara et al 2020(124)	June - July	HCWs with direct patient contact working in an oncology unit in either of the following hospitals the Queen Elizabeth Hospital Kings Lynn NHS Foundation Trust (QE), North West Anglia NHS Foundation Trust (Peterborough City Hospital, NWA), and Cambridge University Hospitals NHS Foundation Trust (CUH).	13.3% * using Luminex assay on day 28

The lowest seroprevalence was seen in a teaching hospital in Rome, Italy during the months of March – April 2020, reporting a seroprevalence of 0.7% based on IgG antibodies and 0% based on IgM (68). The highest seroprevalence (45.3%) was reported in March – April 2020 in a University Hospital in London (108). Figure 2, chart A shows the seroprevalence of HCWs by country overtime. The majority of studies report a seroprevalence < 10% between March – August 2020. A few studies predominately based in the UK report a seroprevalence 20- 45% among HCWs during this time period (21,87,108,109,112,117,118,122).

**Figure 2:** Chart A; shows the seroprevalence of HCWs by country overtime. Chart B: shows the seroprevalence of HCWs overtime stratified by risk group. Chart C: shows the seroprevalence of community studies overtime by country. Chart D: shows the seroprevalence of outbreak studies overtime stratified by country and subgroup.

Figure 2, chart B shows the seroprevalence of HCWs categorised by their risk of exposure to SARS-CoV-2 patients over time. All subgroups with a seroprevalence of >30% belonged to either medium or high risk. The majority (63/75) of the subgroups had a seroprevalence of less than 20% regardless of their risk.

There was no significant difference in seroprevalence amongst HCWs when stratified by country (Figure 3). There is a large amount of heterogeneity between the studies ( $I^2$  value = 99.3%,  $p = 0.00$ ). There was no reduction in heterogeneity when moderate risk of bias studies were removed. Similarly, when the seroprevalence amongst HCWs was stratified by their risk of exposure to SARS-CoV-2 patients there was no significant difference (supplementary figure 1).

**Figure 3:** Forest plot of the seroprevalence among HCWs stratified by country.

### Community Studies

In total 33 studies were set in the community, spanning 13 countries. The studies collected data between February 2020 - August 2020 (Table 4). Ten of these studies collected samples from blood donors; four studies used residual serum samples from clinics, laboratories and hospital facilities; one study used tissues samples and the remaining studies were randomised population- based studies.

**Table 4:** Studies reporting the seroprevalence in a community setting, dates the studies were conducted, population studied and the overall seroprevalence

Country	Author, year	Time period	Population	Total Seroprevalence (95% CI)
Belgium	Herzog et al 2020(22)	30 March -5 July	Residual sera from ten private diagnostic laboratories in Belgium.	30 March – 5 April 2.90% (2.3-3.4%) .20 – 26 April 6% (5.1-7.1%). 18 – 25 May 6.9% (5.9-8). 8 – 13 June 5.5% (4.7-6.5%). 29 June – 4 July 4.5% (3.7-5.4%)

	Iversen et al 2020(30)	15th April and 23rd April	HCWS and blood donors in the Capital Region of Denmark	HCWS - 4.04% (3.82–4.27). Blood Donors 3.04% (2.58–3.57)
Denmark	Erikstrup et al 2020(31)	6th April to 3rd May	Blood Donors in Denmark	2% (1.8–2.2)
	Petersen et al 2020(34)	27th April – 1st May	Residents of the Faroe Islands	0.6% (0.2%–1.2%)
	Germain et al 2020(35)	1st November 2019 to 16th March 2020	All tissue donors at Lille Tissue bank	1.70%
	Grzelak et al 2020(37)	20th March	A cohort of pauci-symptomatic individuals in Crepy-en-Valois. Blood donors from the Etablissement Français du Sang (EFS) in Lille (France)	Blood donors mean of 3%. Pauci symptomatic cohort mean of 32%.
France	Carrat et al 2020(38)	1st April - 27th May	Residents from Ile-de-France (IDF) or Grand Est (GE) or Nouvelle-Aquitaine (NA)	6.70%
	Gallian et al 2020(39)	Last week of March to the first week of April	Blood Donors	2.70%
	Simon et al 2020(44)	February - April 2020	Patients with IMIDs with and without continuous cytokine blockade. HCWs and a cohort of healthy participants unrelated to health care	Healthy participants 2.27% HCWs 4.2%. IMIDs on cytokine inhibition 0.75%. IMIDs not on cytokine inhibition 3.08%
Germany	Fischer et al 2020(45)	9th March - 3rd June	Blood donors in three German federal states North Rhine-Westphalia, Lower Saxony and Hesse	0.91% (0.58–1.24%)
	Aziz et al 2020(53)	24th April -30th June	Individuals enrolled in the Rhineland Study an ongoing community-based prospective cohort study in people aged 30 years and above in the city of Bonn, Germany. Group I all living participants who had been enrolled in the Rhineland Study until March 18, 2020. Group II individuals who were eligible for but had not yet participated in the Rhineland Study.	Group I: 0.97% (0.72–1.30). Group II: 1.94% (0.84–4.42)
Greece	Bogogiannidou et al 2020(58)	March and April	Individuals who visited the laboratories for a check-up, chronic disease follow-up or other reasons unrelated to COVID-19 in the whole of Greece	March: 0.24% (0.03–0.45%). April 0.42% (0.23–0.61%)
Iceland	Gudbjartsson et al 2020(61)	January - July	Two groups of qPCR-positive Icelanders and six groups of Icelanders who had not been qPCR-tested or who had been tested and had received a negative result	4.22%
	Valenti et al 2020(63)	24th February - 8th April	Blood donors in Milan	5.07%

	Vena et al 2020(65)	March and April	Residents living in Liguria and Lombardi regions	11.00%
Italy	Percivalle et al 2020(67)	18th March - 6th April	Registered blood donors in Lodi Italy	23.00%
	Fiore et al 2020(76)	1st May - 31st May	Blood donors in Apulia region, South Eastern Italy	0.99%
	Pagani et al 2020(77)	18th May - 7th June	Residents of Castiglione D'Adda	22.6% (17.2-29.1%)
The Netherlands	Slot et al 2020(81)	1st - 15th April	Plasma donations	2.60%
Luxembourg	Snoeck et al 2020(82)	15th April - 5th May	Population of Luxembourg	1.97%
	Montenegro et al 2020(92)	21 April to 24 April 2020 (Study population A) and from 29 April to 5 May 2020 (Study population B)	Population A: individuals registered in a primary health care centre, from a community area of Barcelona, Spain. Population B: Patients from GPs in Barcelona presenting with mild-moderate symptoms of COVID but no diagnosis of COVID	Population A: 5.47% (3.44-8.58%). Population B: 38.49% (34.78%-42.33%)
Spain	Soriano et al 2020(94)	April - May	Asymptomatic adults in Madrid	13.80%
	Pollan et al 2020(95)	27th April - 11th May	Spanish households	5% (4.7-5.4%) * based on POC testing
	Castro Dopico et al 2020(98)	30th March - 23rd August	Blood Donors and pregnant women in Stockholm	13.7% (9.5-19.3%) * estimated by ENS Learner
Sweden	Roxhed et al 2020(101)	20th April	Households in Stockholm	4.4% (2.4%-6.3%) * for IgG
	Lundkvist et al 2020(102)	17th-18th June	Residents of Norra Djurgårdsstaden and Tensta in Stockholm	15.00%
Switzerland	Stringhini et al 2020(104)	6th April - 9th May	Residents from the Canton of Geneva	7.90%
	Thompson et al 2020(107)	17th March - 19th May 2020	Blood donors in Scotland	3.17%
	Wells et al 2020(114)	27th April - 2nd June	Participants of the Twins UK Cohort Study	12.00%
	The Government of Jersey 2020(115)	29th April - 5th May	Residents in Jersey over 16 years of age	3.1% (+/- 1.3%)
UK	Biobank 2020(120)	27th May - 14th August	UK Biobank participants	8.2% (7.9%-8.7%)
	Public Health England 2020(121)	May	Healthy adult blood donors, supplied by the NHS Blood and Transplant (NHS BT)	8.5% (6.9-10%) * this is adjusted
	Ward et al 2020(126)	20th June - 13th July	Residents in England over the age of 18 years	6% (5.8-6.1%) * adjusted for test performance and re-weighted for sampling

The overall lowest seroprevalence was reported in Greece in March 2020 of 0.24% (0.03-0.45%) (58). The same study reported an increase in seroprevalence in April of 0.42% (0.23-0.61%). The overall highest seroprevalence was reported in Lodi, Italy during the months of April and March at 23% (67). The majority of studies reported an overall seroprevalence of less than 10% during the months of February – August 2020 (Figure 2C).

### Age

Many of the community studies report the seroprevalence among different age groups. There is significant heterogeneity between the results. In general, lower seroprevalences were reported at the extremes of age. Several studies report a higher seroprevalence among the over 50 age group (34,44,65,76,77,95). In contrast some studies report a higher seroprevalence in the less than 30 years age group, these include studies from Switzerland, The Netherlands, Denmark, France, Luxembourg and the UK (38,81,82,104,120,126).

### Gender

In the majority of community studies there was no significance difference identified by gender. However, two studies reported a significantly higher number of female participants having antibodies against SARS-CoV2 (38,65). Carrat et al investigated the seroprevalence in three administrative regions of France Ile-de-France (IDF), Grand Est (GE) and Nouvelle-Aquitaine (NA) and reported a significant association of antibodies associated with the female gender only in Nouvelle-Aquitaine (38). Similarly, Vena et al report a significantly higher seroprevalence among female participants in five administrative regions in Italy (65).

### Blood donors

Many studies report the seroprevalence in blood donors as they are usually healthy individuals who represent the general population. There was a large variation in seroprevalence among blood donors between countries and overtime. The lowest seroprevalence in blood donors was reported in Germany between March and June 2020 of 0.91% (0.58–1.24%) (45). In contrast Percivalle et al reported the highest seroprevalence amongst Italian blood donors in April, living in the Lodi Red Zone of 23.3% (67). The Lombardi Red Zone is an area of 10 municipalities that were put in total social and commercial lockdown from the 23<sup>rd</sup> February 2020(67).The same study reports a seroprevalence of 1.67% in February 2020. In addition, a study in the South East of Italy reports a seroprevalence on 0.99% in May 2020(76).

Similar variations of estimates of seroprevalence were reported in blood donors in the UK. A study conducted in Scotland reported a seroprevalence of 3.17% between the months of March – May 2020(107). A seroprevalence of 8.5% (6.9-10%) was reported in blood donors across England in May (121).

### **Children/ Schools**

Six studies investigated the seroprevalence in school/university settings or among children only, across 5 different countries (41,55,60,105,110,125). Four of the studies examined the seroprevalence in schools (41,55,105,125). The lowest seroprevalence was reported in Germany; 0.6% among students in grade 8–11 and their teachers in 13 secondary schools in eastern Saxony between the months of May – June 2020 (55). The highest seroprevalence

of 11.7% was reported in students and teachers across schools in England between June-July 2020 (10.5-13.3%) (125).

Fontanet et al investigated the seroprevalence among pupils and teachers in primary schools exposed to a SAR-CoV2 outbreak in Paris and reported an overall seroprevalence of 10.4% (41). They noted that 41.4% of infected children had asymptomatic infection compared to 9.9% of seropositive adults (41).

One study examined at the seroprevalence among university students and staff in Greece (60). They reported an overall seroprevalence of 1%, with no significant difference by age, gender, school or position (60).

## Outbreaks

Seven studies across four countries that investigated the seroprevalence following an outbreak of SAR-CoV2 (19,37,41,50,54,119,123) (Supplementary Table 1). Two of the studies were conducted in the UK and reported a high prevalence of antibodies against SARS-CoV2 in residents and staff in care homes/nursing homes where there had been a recent SARS-CoV2 outbreak (119,123). They report a high prevalence of antibodies against SARS-CoV2. Ladhani et al estimated a seroprevalence of 77.9% (73.6-81.7%) and Nsn et al report a seroprevalence of 71.8% (119,123).

In contrast four studies investigated the seroprevalences in the residents or blood donors in communities where there has been an outbreak (19,37,50,54). They report much lower rates of seroprevalence compared to nursing home outbreaks. Grzelak et al investigated the

seroprevalence of pauci-symptomatic individuals in Crepy-en-Valois France and blood donors in the surrounding region following an outbreak; they reported a seroprevalence of 3% in blood donors and 32% in the pauci-symptomatic individuals (37). Similarly studies in Germany following community outbreaks report low rates of seroprevalence among residents. Streeck et al reported a prevalence of SARS-CoV-2 antibodies of 13.6% and Weis et al reported a seroprevalence of 8.4% (50,54). Figure 2, chart D shows the seroprevalence of these outbreak studies overtime.

### **Pregnancy**

Three studies examined the seroprevalence of SARS-CoV-2 in pregnant women (42,74,88). Two of these studies are conducted in Italy between April – June 2020 reported a prevalence of SARS-CoV-2 antibodies of 10.1% and 14.3% in pregnant women in their first trimester screening or at delivery (74,88). The third study estimated a seroprevalence of 8% among pregnant women admitted to the delivery room in France in May 2020 (42). Mattern et al found that the seroprevalence among pregnant women was similar to that of the general public (42).

### **Assays**

In total 45 different commercial assays and 22 in-house assays were used. The majority of studies used more than one assay. Of the commercial assays 11 were enzyme-linked immunosorbent assay (ELISA), six were chemiluminescent microparticle immunoassays, two were based on flow cytometry and 26 were point of care tests (POC). The most commonly used commercial assay was the SARS-CoV-2 (IgA/IgG) ELISA EUROIMMUN Medizinische

Labordiagnostik, Lübeck, Germany (supplementary table 2).

## Discussion

Our systematic review demonstrates a large variation in the seroprevalence of SARS-CoV-2 antibodies throughout Europe in the first half of 2020.

HCWs in the UK had a much higher seroprevalence compared to HCWs in the rest of Europe during the months of March and August 2020. There are nine studies which took place in UK and six of them reported a seroprevalence of more 20% among HCWs (108,109,112,117,118,122). In contrast Italy reports a low seroprevalence among HCWs. Of 10 studies among HCWs in Italy, nine reported a seroprevalence of SARS-CoV-2 antibodies of less than 10% (62,68–73,78,79). Both countries included studies from a mixture of high, medium and low risk HCWs and during this time both countries had high numbers of SARS-CoV-2 infections.

In health care settings the risk to HCWs of SARS CoV2 exposure will be determined by the COVID19 caseload coming though the facility and the application of infection control measures. Infection control practices in relation to personal protective equipment (PPE) may in part explain some of the differences.

Between European countries there are differences in the recommended PPE. The UK government guidelines on PPE include the use of eye/face protection, filtering facepiece class 3 (FFP3) respirator, disposable fluid-repellent coverall, and disposable gloves for aerosol-generating procedures and higher-risk acute care areas. For all inpatient ward

settings eye/face protection, fluid-resistant (type IIR) surgical mask (FRSM), disposable plastic apron, and disposable gloves are recommended (130).

In comparison the National Institute of Health in Italy recommended that all HCWs wear a full-length gown with long sleeves, hairnet, goggles, gloves and surgical mask in the case of low-risk patients, and hairnet, googles or face-shield, FFP3 mask, water-resistant gown with long sleeves, and two pairs of gloves (second one covering the wrist of gown sleeves) for high-risk patients and SARS-CoV-2 positive patients (68).

Although the availability and differences in PPE across European countries may partly explain the difference in seroprevalence seen in HCWs, there are other factors that require consideration. For example, differences in public health strategies and the time of their implementation such as the public wearing face masks, closure of educational settings and other public facilities. Furthermore, differences in adherence to infection control measures such as hand hygiene and social distancing could also explain the difference in seroprevalence seen among HCWs across Europe.

Our systematic review found that in the majority of studies in Europe there was no difference in seroprevalence between female and male participants. Our findings are in keeping with a meta-analysis which showed there was no difference in the proportion of males and females with confirmed COVID-19(131).

However, there is strong evidence that males are more likely to have more severe disease compared to females. A meta-analysis looking at 92 studies world-wide concluded that male patients have almost three times the odds of requiring intensive treatment unit (ITU) admission and have higher odds of death compared to females (131). Similarly, Castro-

Dopico et al reported that severe disease was associated with virus -specific IgA and that IgA responses were lower in females compared to males (98).

Throughout the current pandemic there has been debate on the role of children in the transmission of SARS-CoV-2 and the need for school closure to slow the pandemic. In this review three studies were in schools not involved in an outbreak of SARS-CoV-2. A study in Germany reported the lowest seroprevalence among students and teachers in a school of 0.6% considered by the authors to be in keeping with local surveillance data of the surrounding community (55). Ulyte et al reported that seroprevalence is inversely related to age in their school study (105). They conclude this could be due to the lack of social distancing among young children and differences in immune response (105). In contrast Ladhani et al reported no significant difference between the seroprevalence in students compared to staff (125). However, all studies concluded that there was no major transmission in schools and that the majority of children were asymptomatic or had mild symptoms (55,105,125). This review highlights the need for more school-based studies investigating the seroprevalence among staff and students to fully understand transmission dynamics and immune responses throughout the pandemic.

In studies conducted during local outbreaks there was a noticeable difference between those conducted in care/nursing homes compared to community and school settings. Those that took place in care/ nursing homes reported a seroprevalence as high as 77.9%, whereas those in a community setting reported a seroprevalence ranging from 3% - 42.4% and those in a school reported a seroprevalence of 10.4%(19,37,41,50,54,119) This large discrepancy

could be attributable to the close proximity of care/nursing home residents, shared living spaces and the intimate care and handling of residents by staff.

### **Limitations**

This meta-analysis had several limitations. Firstly, of the 109 studies included in this review, not all of them could be included in sub-analysis as complete data sets could not be retrieved from every study and data quality was heterogeneous. In addition, the majority of studies were performed either in the UK, Italy, Spain or Germany. There was a large gap in studies being performed in Eastern European countries. Those studies performed in the UK predominately took place in the South of England. Furthermore, many of the studies were pre-print articles that had not undergone peer-review.

### **Conclusion**

This systematic review and metanalysis highlights substantial heterogeneity between countries, within countries, among professions, and among settings. This heterogeneity, in addition to indicating the general trajectory of the pandemic in different regions, will also be driven by a variety of other factors including governmental policies and restrictions, local guidelines and restrictions, availability of PPE, the time period when the study was conducted and serological test performance. Nevertheless, seroprevalence studies yield large amounts of useful, locally relevant information and should be regularly repeated as the pandemic evolves and local guidelines and restrictions change. As testing standardizes and new studies are reported they will also help identify different national experiences across Europe and provide a means to distil best pandemic control practices for the future.

Finally, as new variants of SARS-CoV-2 now emerge, and many countries prepare for future waves it is vital that regular seroprevalence studies are conducted to aid control in the context of vaccine implementation.

### **Author Contributions**

**NMV** – wrote the protocol, develop search terms, conducted searches, screened studies, extract data, conducted data analysis and meta-analysis and wrote the final draft.

**DH** – wrote the protocol, develop search terms, conducted data analysis and meta-analysis and proofread the final draft.

**BS** - wrote the protocol, develop search terms, conducted searches, screened studies and proofread the final draft.

**AK** – extracted data and proofread the final draft.

**CN** – helped with writing and proofreading the final draft

**NF** – wrote the protocol, develop search terms, helped to conduct data analysis and meta-analysis and proofread the final draft.

All authors have approved and read the final manuscript.

### **Acknowledgements**

NC and DH are affiliated to the NIHR Health Protection Research Unit (HPRU) in Gastrointestinal Infections at University of Liverpool, in partnership with Public Health England (PHE), in collaboration with University of Warwick. NC and DH are based at The University of Liverpool. NF and DH are affiliated to the NIHR HPRU Emerging and Zoonotic Infections, a partnership between PHE, the University of Liverpool in collaboration with the Liverpool School of Tropical Medicine and the University of Oxford. The views expressed are

those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, HPRU or PHE.

## **Supplementary Files**

**Supplementary Table 1:** *Studies reporting the seroprevalence in an outbreak setting, dates the studies were conducted, population studied and the overall seroprevalence*

**Supplementary Table 2:** *Commercial assays and their specificity and sensitivity according to the manufacturer. In some cases, the manufacturer's specificity and sensitivity were unable to be found, so evaluation study data was used instead.*

**Supplementary figure 1:** *Forest plot of the seroprevalence among HCWs stratified by risk of exposure to SARS-CoV-2 patients.*

## References:

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2020 Nov 18]. Available from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
2. Kutti-Sridharan G, Vegunta R, Vegunta R, Mohan BP, Rokkam VRP. SARS-CoV2 in Different Body Fluids, Risks of Transmission, and Preventing COVID-19: A Comprehensive Evidence-Based Review. *Int J Prev Med* [Internet]. 2020 [cited 2020 Nov 18];11:97. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33042494>
3. Li Y, Qian H, Hang J, Chen X, Hong L, Liang P, et al. Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant. *medRxiv* [Internet]. 2020 Jan 1;2020.04.16.20067728. Available from: <http://medrxiv.org/content/early/2020/04/22/2020.04.16.20067728.abstract>
4. Anderson EL, Turnham P, Griffin JR, Clarke CC. Consideration of the Aerosol Transmission for COVID-19 and Public Health. *Risk Anal* [Internet]. 2020 [cited 2020 Nov 18];40(5):902–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32356927>
5. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* [Internet]. 2020 Apr 30 [cited 2020 Nov 18];382(18):1708–20. Available from: <http://www.nejm.org/doi/10.1056/NEJMoa2002032>
6. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ* [Internet]. 2020 Apr 2 [cited 2020 Nov 18];369:m1375. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32241884>
7. Zhou J, Tan Y, Li D, He X, Yuan T, Long Y. Observation and analysis of 26 cases of asymptomatic SARS-CoV2 infection. *J Infect* [Internet]. 2020 Jul [cited 2020 Nov 18];81(1):e69–70. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32251687>
8. European Centre for Disease Prevention and control. Population-wide testing of SARS-CoV-2: country experiences and potential approaches in the EU/EEA and the United Kingdom European Commission request Definition [Internet]. 2020 [cited 2020 Oct 1]. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-population-wide-testing-country-experiences.pdf>
9. World Health Organization. COVID-19 Strategy Update April 2020 [Internet]. 2020 [cited 2020 Nov 20]. Available from: [https://www.who.int/docs/default-source/coronavirus/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0\\_19](https://www.who.int/docs/default-source/coronavirus/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19)
10. Iacobucci G. Covid-19: Mass population testing is rolled out in Liverpool. *BMJ* [Internet]. 2020 Nov 3 [cited 2020 Nov 18];371:m4268. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33144291>
11. Burgess S, Ponsford MJ, Gill D. Are we underestimating seroprevalence of SARS-CoV-2? *BMJ* [Internet]. 2020 Sep 3 [cited 2020 Nov 18];370:m3364. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32883673>
12. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. *BMJ* [Internet]. 2020 Sep 8 [cited 2020 Nov 19];370:m3325. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/32900692>

13. Mafopa NG, Russo G, Wadoum REG, Iwerima E, Batwala V, Giovanetti M, et al. Seroprevalence of Ebola virus infection in Bombali District, Sierra Leone. *J Public Health Africa* [Internet]. 2017 Dec 31 [cited 2020 Nov 20];8(2):732. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29456826>
14. Béraud G, Abrams S, Beutels P, Dervaux B, Hens N. Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. *Euro Surveill* [Internet]. 2018 [cited 2020 Nov 20];23(25). Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29945697>
15. Nguyen K, Peer N, Mills E, Kengne A. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. *PLoS One* [Internet]. 2016 [cited 2020 Dec 28];11(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/27008536/>
16. Wang N. How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial [Internet]. 2018 [cited 2021 Mar 30]. Available from: [https://www.researchgate.net/publication/325486099\\_How\\_to\\_Conduct\\_a\\_Meta-Analysis\\_of\\_Proportions\\_in\\_R\\_A\\_Comprehensive\\_Tutorial](https://www.researchgate.net/publication/325486099_How_to_Conduct_a_Meta-Analysis_of_Proportions_in_R_A_Comprehensive_Tutorial)
17. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J Clin Epidemiol* [Internet]. 2014 Aug 1 [cited 2021 Mar 30];67(8):897–903. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24794697>
18. Orth-Höller D, Eigentler A, Weseslindtner L, Möst J. Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection. *Emerg Microbes Infect* [Internet]. 2020;9(1):1692–4. Available from: <http://europepmc.org/abstract/MED/32654611>
19. Knabl L, Mitra T, Kimpel J, Roessler A, Volland A, Walser A, et al. High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl. *medRxiv* [Internet]. 2020 Jan 1;2020.08.20.20178533. Available from: <http://medrxiv.org/content/early/2020/08/22/2020.08.20.20178533.abstract>
20. Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. *ESMO open* [Internet]. 2020 Sep;5(5). Available from: <https://doi.org/10.1136/esmoopen-2020-000889>
21. Reiter T, Pajenda S, Wagner L, Gaggl M, Atamaniuk J, Holzer B, et al. Covid-19 serology in nephrology health care workers. *medRxiv* [Internet]. 2020 Jan 1;2020.07.21.20136218. Available from: <http://medrxiv.org/content/early/2020/07/26/2020.07.21.20136218.abstract>
22. Herzog S, De Bie J, Abrams S, Wouters I, Ekinci E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional nationwide study of residual samples. *medRxiv* [Internet]. 2020 Jan 1;2020.06.08.20125179. Available from: <http://medrxiv.org/content/early/2020/07/30/2020.06.08.20125179.abstract>
23. Berardis S, Verroken A, Vetillart A, Struyf C, Gilbert M, Gruson D, et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. *J Cyst Fibros* [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7418700>
24. Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *JAMA - J Am Med Assoc* [Internet]. 2020;324(2):195–7. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0->

85086874531&doi=10.1001%2Fjama.2020.11160&partnerID=40&md5=963394d5851  
2419685c8fb2d69f16e62

- 25. Martin C, Montesinos I, Dauby N, Gilles C, Dahma H, Wijngaert S Van Den, et al. Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff. *J Hosp Infect* [Internet]. 2020 [cited 2020 Dec 23];106(1):102. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316468/>
- 26. Desombere I, Mortgat L, Duysburgh E. COVID-19 study: 8.4% of Belgian health workers have antibodies to SARS-CoV-2 [Internet]. Sciensano press release. 2020. Available from: <https://www.sciensano.be/en/press-corner/covid-19-study-84-belgian-health-workers-have-antibodies-sars-cov-2>
- 27. Blaïron L, Mokrane S, Wilmet A, Dessimy G, Kabamba-Mukadi B, Beuvinga I, et al. Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak. *J Infect* [Internet]. 2020; Available from: <http://europepmc.org/abstract/MED/32739485>
- 28. Jerković I, Ljubić T, Bašić Ž, Kružić I, Kunac N, Bežić J, et al. SARS-CoV-2 Antibody Seroprevalence in Industry Workers in Split-Dalmatia and Šibenik-Knin County, Croatia. *J Occup Environ Med* [Internet]. 2020 Sep 8 [cited 2020 Dec 21]; Available from: <https://journals.lww.com/10.1097/JOM.0000000000002020>
- 29. Vilibic-Cavlek T, Stevanovic V, Tabain I, Betica-Radic L, Sabadi D, Peric L, et al. Severe acute respiratory syndrome coronavirus 2 seroprevalence among personnel in the healthcare facilities of Croatia, 2020. *Rev Soc Bras Med Trop* [Internet]. 2020;53:e20200458. Available from: <https://europepmc.org/articles/PMC7451497>
- 30. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. *Lancet Infect Dis* [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7398038>
- 31. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *medRxiv* [Internet]. 2020 Jan 1;2020.04.24.20075291. Available from: <http://medrxiv.org/content/early/2020/04/28/2020.04.24.20075291.abstract>
- 32. Jespersen S, Mikkelsen S, Greve T, Kaspersen KA, Tolstrup M, Boldsen JK, et al. SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region. *medRxiv* [Internet]. 2020 Jan 1;2020.08.10.20171850. Available from: <http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171850.abstract>
- 33. Laursen J, Petersen J, Didriksen M, Iversen KK, Ullum H. Prevalence of SARS-CoV-2 IgG/IgM antibodies among Danish and Swedish Falck emergency and non-emergency healthcare workers [Internet]. *medRxiv*; 2020. Available from: <http://europepmc.org/abstract/PPR/PPR219363>
- 34. Petersen MS, Strom M, Christiansen DH, Fjallsbak JP, Eliasen EH, Johansen M, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands. *Emerg Infect Dis* [Internet]. 2020;26(11). Available from: [http://europepmc.org/search?query=\(DOI:10.3201/eid2611.202736\)](http://europepmc.org/search?query=(DOI:10.3201/eid2611.202736))
- 35. Germain N, Herwegh S, Hatzfeld AS, Bocket L, Prevost B, Danze PM, et al. Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France

[Internet]. medRxiv; 2020. Available from:  
<http://europepmc.org/abstract/PPR/PPR213447>

36. Solodky ML, Galvez C, Russias B, Detourbet P, N'Guyen-Bonin V, Herr A-L, et al. Lower detection rates of SARS-CoV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. *Ann Oncol* [Internet]. 2020 [cited 2020 Dec 21];31(8):1087. Available from:  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252166/>

37. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. *Sci Transl Med* [Internet]. 2020 Aug 17 [cited 2020 Dec 21];12(559). Available from: <https://europepmc.org/article/MED/32817357>

38. Carrat F, de Lamballerie X, Rahib D, Blanche H, Lapidus N, Artaud F, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study [Internet]. medRxiv; 2020. Available from: <http://europepmc.org/abstract/PPR/PPR215593>

39. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res* [Internet]. 2020 Sep;181:104880. Available from:  
<https://europepmc.org/articles/PMC7362788>

40. sermet isabelle, temmam sarah, huon christele, behillil sylvie, gadjos vincent, bigot thomas, et al. Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated Multisystem Inflammatory Syndrome in children. medRxiv [Internet]. 2020 Jan 1;2020.06.29.20142596. Available from:  
<http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142596.abstract>

41. Fontanet A, Grant R, Tondeur L, Madec Y, Grzelak L, Cailleau I, et al. SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission. medRxiv [Internet]. 2020 Jan 1;2020.06.25.20140178. Available from:  
<http://medrxiv.org/content/early/2020/06/29/2020.06.25.20140178.1.abstract>

42. Mattern J, Vauloup-Fellous C, Zakaria H, Benachi A, Carrara J, Letourneau A, et al. Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France. Spradley FT, editor. *PLoS One* [Internet]. 2020 Oct 15 [cited 2020 Dec 21];15(10):e0240782. Available from:  
<https://dx.plos.org/10.1371/journal.pone.0240782>

43. Péré H, Wack M, Védie B, Guinet ND, Najiby KC, Janot L, et al. Sequential SARS-CoV-2 IgG assays as confirmatory strategy to confirm equivocal results: Hospital-wide antibody screening in 3,569 staff health care workers in Paris. *J Clin Virol* [Internet]. 2020 Sep; Available from: <https://europepmc.org/articles/PMC7470734>

44. Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. *Nat Commun* [Internet]. 2020 Jul;11(1):3774. Available from: <https://europepmc.org/articles/PMC7382482>

45. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Euro Surveill* [Internet]. 2020 Jul;25(28). Available from:  
<https://europepmc.org/articles/PMC7376847>

46. Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, Borchers N, et al.

Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. Kalayci Ö, editor. *Pediatr Allergy Immunol* [Internet]. 2020 Oct 18 [cited 2020 Dec 21];31(7):841–7. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/pai.13278>

47. Brehm TT, Schwinge D, Lampalzer S, Schlicker V, Kuechen J, Thompson M, et al. High effectiveness of multimodal infection control interventions in preventing SARS-CoV-2 infections in healthcare professionals: a prospective longitudinal seroconversion study. *medRxiv* [Internet]. 2020 Jan 1;2020.07.31.20165936. Available from: <http://medrxiv.org/content/early/2020/08/02/2020.07.31.20165936.abstract>

48. Behrens GMN, Cossmann A, Stankov M V, Witte T, Ernst D, Happle C, et al. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. *Infection* [Internet]. 2020 Aug;48(4):631–634. Available from: <https://europepmc.org/articles/PMC7286418>

49. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. *J Clin Virol* [Internet]. 2020 Jul;128:104437. Available from: <https://europepmc.org/articles/PMC7219425>

50. Streeck H, Schulte B, Kuemmerer B, Richter E, Hoeller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. *medRxiv* [Internet]. 2020 Jan 1;2020.05.04.20090076. Available from: <http://medrxiv.org/content/early/2020/06/02/2020.05.04.20090076.abstract>

51. Krähling V, Kern M, Halwe S, Müller H, Rohde C, Savini M, et al. Title: Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area. [cited 2020 Dec 21]; Available from: <https://doi.org/10.1101/2020.05.20.20107730>

52. Schmidt SB, Grüter L, Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. Adrish M, editor. *PLoS One* [Internet]. 2020 Jun 25 [cited 2020 Dec 21];15(6):e0235417. Available from: <https://dx.plos.org/10.1371/journal.pone.0235417>

53. Aziz A, Corman V, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany [Internet]. medRxiv; 2020. Available from: <https://doi.org/10.1101/2020.08.24.20181206>

54. Weis S, Scherag A, Baier M, Kiehntopf M, Kamradt T, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study. *medRxiv* [Internet]. 2020 Jan 1;2020.07.15.20154112. Available from: <http://medrxiv.org/content/early/2020/07/17/2020.07.15.20154112.abstract>

55. Armann JP, Unrath M, Kirsten C, Lueck C, Dalpke A, Berner R. Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seroprevalence and transmission rates. *medRxiv* [Internet]. 2020 Jan 1;2020.07.16.20155143. Available from: <http://medrxiv.org/content/early/2020/07/28/2020.07.16.20155143.abstract>

56. Epstude J, Harsch IA. Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic. *GMS Hyg Infect Control* [Internet]. 2020;15:Doc18. Available from: <https://europepmc.org/articles/PMC7376972>

57. Hoffmann S, Spallek J, Gremmels H-D, Schiebel J, Hufert F. Testing the backbone of

the healthcare system: a prospective serological-epidemiological cohort study of healthcare workers in rural Germany [Internet]. Research Square; 2020. Available from: <http://europepmc.org/abstract/PPR/PPR220081>

58. Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro Surveill* [Internet]. 2020 Aug;25(31). Available from: <https://europepmc.org/articles/PMC7459271>

59. Psichogiou M, Karabinis A, Pavlopoulou ID, Basoulis D, Petsios K, Roussos S, et al. Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. *medRxiv* [Internet]. 2020 Jan 1;2020.06.23.20137620. Available from: <http://medrxiv.org/content/early/2020/06/23/2020.06.23.20137620.abstract>

60. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, et al. Seroprevalence of antibodies against SARS-CoV-2 among the personnel and students of the national and kapodistrian university of athens, greece: A preliminary report. *Life* [Internet]. 2020;10(9):1–8. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091318842&doi=10.3390%2Flife10090214&partnerID=40&md5=3d9928b21aede787d8edb6606006e92a>

61. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med* [Internet]. 2020; Available from: <http://europepmc.org/abstract/PMC/PMC7494247>

62. Plebani, Padoan, Fedeli, Schievano, Vecchiato, Lippi, et al. SARS-CoV-2 serosurvey in health care workers of the Veneto Region. *Clin Chem Lab Med* [Internet]. 2020 [cited 2021 Jan 1];58(12). Available from: <https://pubmed.ncbi.nlm.nih.gov/32845861/>

63. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. *medRxiv* [Internet]. 2020 Jan 1;2020.05.11.20098442. Available from: <http://medrxiv.org/content/early/2020/05/31/2020.05.11.20098442.abstract>

64. Pancrazzi A, Magliocca P, Lorubbio M, Vaggelli G, Galano A, Mafucci M, et al. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity. *Clin Biochem* [Internet]. 2020;84:87–92. Available from: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088807240&doi=10.1016%2Fj.clinbiochem.2020.07.002&partnerID=40&md5=fdf2066950d4259b654f1f1c5086359e>

65. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. *J Clin Med* [Internet]. 2020 Aug;9(9). Available from: <https://doi.org/10.3390/jcm9092780>

66. Norsa L, Cosimo P, Indriolo A, Sansotta N, D'Antiga L, Callegaro A. Asymptomatic SARS-CoV-2 infection in patients with inflammatory bowel disease under biologic treatment. *Gastroenterology* [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7448738>

67. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Euro Surveill* [Internet]. 2020 Jun;25(24). Available from: <https://europepmc.org/articles/PMC7315724>

68. Lahner E, Dilaghi E, Prestigiacomo C, Alessio G, Marcellini L, Simmaco M, et al.

Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy. *Int J Environ Res Public Health* [Internet]. 2020 [cited 2020 Dec 20];17(12). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345358/>

69. Fusco FM, Pisaturo M, Iodice V, Bellopede R, Tambaro O, Parrella G, et al. COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study. *J Hosp Infect* [Internet]. 2020 Aug;105(4):596—600. Available from: <https://europepmc.org/articles/PMC7301109>

70. Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. *BMC Pulm Med* [Internet]. 2020 Jul;20(1):203. Available from: <https://europepmc.org/articles/PMC7388425>

71. Amendola A, Tanzi E, Folgori L, Barcellini L, Bianchi S, Gori M, et al. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. *Infect Control Hosp Epidemiol* [Internet]. 2020 Aug;1—2. Available from: <https://europepmc.org/articles/PMC7438626>

72. Carozzi FM, Cusi MG, Pistello M, Galli L, Bartoloni A, Anichini G, et al. Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing. *medRxiv* [Internet]. 2020 Jan 1;2020.07.30.20149567. Available from: <http://medrxiv.org/content/early/2020/08/04/2020.07.30.20149567.abstract>

73. Comar M, Brumat M, Concas MP, Argentini G, Bianco A, Bicego L, et al. COVID-19 experience: first Italian survey on healthcare staff members from a Mother-Child Research Hospital using combined molecular and rapid immunoassays test. *medRxiv* [Internet]. 2020 Apr 22 [cited 2020 Dec 21];2020.04.19.20071563. Available from: <https://www.medrxiv.org/content/10.1101/2020.04.19.20071563v1>

74. Cosma S, Borella F, Carosso A, Sciarrone A, Cusato J, Corcione S, et al. The “scar” of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. *J Med Virol* [Internet]. 2020 Jul; Available from: <https://europepmc.org/articles/PMC7361535>

75. Sandri MT, Azzolini E, Torri V, Carloni S, Tedeschi M, Castoldi M, et al. IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy, Italy. *medRxiv* [Internet]. 2020 Jan 1;2020.05.24.20111245. Available from: <http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111245.abstract>

76. Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *J Med Virol* [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7436723>

77. Pagani G, Conti F, Giacomelli A, Bernacchia D, Rondanin R, Prina A, et al. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening. *J Infect* [Internet]. 2020 Dec 1 [cited 2020 Dec 21];81(6):e10—2. Available from: [https://www.journalofinfection.com/article/S0163-4453\(20\)30629-0/fulltext](https://www.journalofinfection.com/article/S0163-4453(20)30629-0/fulltext)

78. Paderno A, Fiori M, Berretti G, Schreiber A, Mattavelli D, Deganello A, et al. SARS-CoV-

2 infection in healthcare workers: cross-sectional analysis of an Otolaryngology Unit 2 [Internet]. [cited 2020 Dec 21]. Available from: [https://www.entnet.org/sites/default/files/uploads/paderno2\\_sars-cov-2\\_infection\\_in\\_healthcare\\_workers.pdf](https://www.entnet.org/sites/default/files/uploads/paderno2_sars-cov-2_infection_in_healthcare_workers.pdf)

79. Tosato F, Peloso M, Gallo N, Giraudo C, Llanaj G, Cosma C, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Serology in Asymptomatic Healthcare Professionals: Preliminary Experience of a Tertiary Italian Academic Center. medRxiv [Internet]. 2020 Jan 1;2020.04.27.20073858. Available from: <http://medrxiv.org/content/early/2020/05/01/2020.04.27.20073858.abstract>

80. Westerhuis BM, de Bruin E, Chandler FD, Ramakers CRB, Okba NMA, Li W, et al. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands. medRxiv [Internet]. 2020 Jan 1;2020.08.21.20177857. Available from: <http://medrxiv.org/content/early/2020/08/24/2020.08.21.20177857.abstract>

81. Slot E, Hogema B, Reusken CBEM, Reimerink J, Molier M, Karregat JHM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak [Internet]. Research Square; 2020. Available from: <https://doi.org/10.21203/rs.3.rs-25862/v1>

82. Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. medRxiv [Internet]. 2020 Jan 1;2020.05.11.20092916. Available from: <http://medrxiv.org/content/early/2020/05/18/2020.05.11.20092916.abstract>

83. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers [Internet]. medRxiv; 2020. Available from: <https://doi.org/10.1101/2020.08.30.20184309>

84. Dacosta-Urbieto A, Rivero-Calle I, Pardo-Seco J, Redondo-Collazo L, Salas A, Gomez-Rial J, et al. Seroprevalence of SARS-CoV-2 Among Pediatric Healthcare Workers in Spain. Front Pediatr [Internet]. 2020;8. Available from: [http://europepmc.org/search?query=\(DOI:10.3389/fped.2020.00547\)](http://europepmc.org/search?query=(DOI:10.3389/fped.2020.00547))

85. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jimenez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. medRxiv [Internet]. 2020 Jan 1;2020.04.27.20082289. Available from: <http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082289.abstract>

86. Valdivia A, Torres I, Huntley D, Alcaraz MJ, Albert E, de la Asunción C, et al. Caveats in interpreting SARS-CoV-2 IgM+ /IgG- antibody profile in asymptomatic health care workers. J Med Virol [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7436589>

87. Galan I, Velasco M, Casas ML, Goyanes MJ, Rodriguez-Caravaca G, Losa JE, et al. SARS-CoV-2 SEROPREVALENCE AMONG ALL WORKERS IN A TEACHING HOSPITAL IN SPAIN: UNMASKING THE RISK. medRxiv [Internet]. 2020 Jan 1;2020.05.29.20116731. Available from: <http://medrxiv.org/content/early/2020/05/29/2020.05.29.20116731.abstract>

88. Crovetto F, Crispi F, Llurba E, Figueras F, Gómez-Roig MD, Gratacós E. Seroprevalence and presentation of SARS-CoV-2 in pregnancy. Lancet [Internet]. 2020;396(10250):530–1. Available from:

<https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089518432&doi=10.1016%2FS0140-6736%2820%2931714-1&partnerID=40&md5=d1a1beb365755cc3668ff54d05bc525b>

89. Garralda Fernandez J, Molero Vilches I, Bermejo Rodriguez A, Cano de Torres I, Colino Romay EI, Garcia-Arata I, et al. Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain. *medRxiv* [Internet]. 2020 Jan 1;2020.07.26.20162529. Available from: <http://medrxiv.org/content/early/2020/07/29/2020.07.26.20162529.abstract>

90. Olalla J, Correa AM, Martin-Escalante MD, Hortas ML, Martin-Sendarrubias MJ, Fuentes V, et al. Search for asymptomatic carriers of SARS-CoV-2 in healthcare workers during the pandemic: a Spanish experience. *medRxiv* [Internet]. 2020 Jan 1;2020.05.18.20103283. Available from: <http://medrxiv.org/content/early/2020/05/20/2020.05.18.20103283.abstract>

91. Martín V, Fernández-Villa T, Lamuedra Gil de Gomez M, Mencía-Ares O, Rivero Rodríguez A, Reguero Celada S, et al. Prevalence of SARS-CoV-2 infection in general practitioners and nurses in primary care and nursing homes in the Healthcare Area of León and associated factors. *Semergen* [Internet]. 2020;46 Suppl 1:35–9. Available from: <http://europepmc.org/abstract/MED/32646731>

92. Montenegro P, Brotóns C, Fernandez D, Ichazo B, Moral I, Pitarch M, et al. Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain. *Fam Pract* [Internet]. 2020; Available from: <https://academic.oup.com/fampra/advance-article-pdf/doi/10.1093/fampra/cmaa096/33734322/cmaa096.pdf>

93. Moncunill G, Mayor A, Santano R, Jimenez A, Vidal M, Tortajada M, et al. SARS-CoV-2 infections and antibody responses among health care workers in a Spanish hospital after a month of follow-up. *medRxiv* [Internet]. 2020 Jan 1;2020.08.23.20180125. Available from: <http://medrxiv.org/content/early/2020/08/25/2020.08.23.20180125.abstract>

94. Soriano V, Meiriño R, Corral O, Guallar MP. SARS-CoV-2 antibodies in adults in Madrid, Spain. *Clin Infect Dis* [Internet]. 2020 Jun; Available from: <https://europepmc.org/articles/PMC7337724>

95. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* (London, England) [Internet]. 2020 Aug;396(10250):535–544. Available from: <https://europepmc.org/articles/PMC7336131>

96. Barallat J, Fernández-Rivas G, Quirant-Sánchez B, Martínez-Cáceres, Pina M, Matllo J, et al. Seroprevalence of SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. [cited 2020 Dec 21]; Available from: <https://doi.org/10.1101/2020.06.24.20135673>

97. Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, José García-Navarro M, Khosravi-Shahi P. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. *Cancer Treat Rev* [Internet]. 2020 Sep; Available from: <https://europepmc.org/articles/PMC7462449>

98. Castro Dopico X, Hanke L, Sheward DJ, Christian M, Muschiol S, Grinberg NF, et al.

Antibody phenotypes and probabilistic seroprevalence estimates during the emergence of SARS-CoV-2 in Sweden. medRxiv [Internet]. 2020 Jan 1;2020.07.17.20155937. Available from: <http://medrxiv.org/content/early/2020/08/25/2020.07.17.20155937.abstract>

99. Rudberg A-S, Havervall S, Manberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in health care workers. medRxiv [Internet]. 2020 Jan 1;2020.06.22.20137646. Available from: <http://medrxiv.org/content/early/2020/06/23/2020.06.22.20137646.abstract>

100. Lindahl JF, Hoffman T, Esmaeilzadeh M, Olsen B, Winter R, Amer S, et al. High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden [Internet]. Vol. 10, Infection ecology & epidemiology. 2020. p. 1789036. Available from: <http://europepmc.org/abstract/MED/32939231>

101. Roxhed N, Bendes A, Dale M, Mattsson C, Hanke L, Dodig-Crnkovic T, et al. A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood. medRxiv [Internet]. 2020 Jan 1;2020.07.01.20143966. Available from: <http://medrxiv.org/content/early/2020/07/02/2020.07.01.20143966.abstract>

102. Lundkvist Å, Hanson S, Olsen B. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden [Internet]. Vol. 10, Infection ecology & epidemiology. 2020. p. 1806505. Available from: <http://europepmc.org/abstract/MED/32944166>

103. Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Ebner D, Schneider MM, et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region. medRxiv [Internet]. 2020 Jan 1;2020.05.31.20118554. Available from: <http://medrxiv.org/content/early/2020/08/07/2020.05.31.20118554.abstract>

104. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet (London, England) [Internet]. 2020 Aug;396(10247):313–319. Available from: <https://europepmc.org/articles/PMC7289564>

105. Ulyte A, Radtke T, Abela I, Haile S, Blankenberger J, Jung R, et al. Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes [Internet]. medRxiv; 2020. Available from: <http://europepmc.org/abstract/PPR/PPR215541>

106. ALKURT G, MURT A, AYDIN Z, TATLI O, AGAOGLU NB, IRVEM A, et al. Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey. medRxiv [Internet]. 2020 Jan 1;2020.08.19.20178095. Available from: <http://medrxiv.org/content/early/2020/08/22/2020.08.19.20178095.abstract>

107. Thompson CP, Grayson N, Paton R, Bolton JS, Lourenço J, Penman B, et al. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020. medRxiv [Internet]. 2020 Jan 1;2020.04.13.20060467. Available from: <http://medrxiv.org/content/early/2020/07/29/2020.04.13.20060467.abstract>


108. Houlihan C, Vora N, Byrne T, Lewer D, Heaney J, Moore D. SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study. medRxiv. 2020;

109. Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, et al. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. *Lancet Respir Med* [Internet]. 2020 Sep;8(9):885–894. Available from: <https://europepmc.org/articles/PMC7380925>
110. Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt A, et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. *Arch Dis Child* [Internet]. 2020 Nov 23 [cited 2020 Dec 21]; Available from: <https://adc.bmjjournals.org/content/early/2020/11/22/archdischild-2020-320558>
111. Eyre DW, Lumley SF, O'Donnell D, Campbell M, Sims E, Lawson E, et al. Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study. *medRxiv* [Internet]. 2020 Jan 1;2020.06.24.20135038. Available from: <http://medrxiv.org/content/early/2020/06/29/2020.06.24.20135038.1.abstract>
112. Shields A, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. *Thorax* [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7462045>
113. Clarke C, Prendecki M, Dhutia A, Ali MA, Sajjad H, Shivakumar O, et al. High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. *J Am Soc Nephrol* [Internet]. 2020 Sep;31(9):1969–1975. Available from: <https://doi.org/10.1681/ASN.2020060827>
114. Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *J Infect* [Internet]. 2020 Dec 1 [cited 2020 Dec 21];81(6):931–6. Available from: [https://www.journalofinfection.com/article/S0163-4453\(20\)30653-8/fulltext](https://www.journalofinfection.com/article/S0163-4453(20)30653-8/fulltext)
115. The Government of Jersey. SARS-CoV-2: Prevalence of antibodies in Jersey. Jersey, UK, 2020. [Internet]. 2020 [cited 2020 Dec 21]. Available from: [www.gov.je/statistics](http://www.gov.je/statistics)
116. Poulikakos D, Sinha S, Kalra PA. SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England. *J Clin Virol* [Internet]. 2020 Aug;129:104545. Available from: <https://europepmc.org/articles/PMC7338856>
117. Khalil A, Hill R, Wright A, Ladhani S, O'Brien P. SARS-CoV-2-specific antibody detection in healthcare workers in a UK maternity Hospital: Correlation with SARS-CoV-2 RT-PCR results. *Clin Infect Dis* [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7454457>
118. Grant JJ, Wilmore SMS, McCann NS, Donnelly O, Lai RWL, Kinsella MJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. *Infect Control Hosp Epidemiol* [Internet]. 2020 Aug;1–3. Available from: <https://europepmc.org/articles/PMC7438618>
119. Ladhani SN, Jeffery-Smith AJ, Patel M, Janarthanan R, Fok J, Crawley-Boevey E, et al. High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19; a prospective cohort study in England. *medRxiv* [Internet]. 2020 Jan 1;2020.08.10.20171413. Available from: <http://medrxiv.org/content/early/2020/08/12/2020.08.10.20171413.abstract>
120. UK Biobank. UK Biobank SARS-CoV2 Serology Study (Weekly Report - 21 July 2020) [Internet]. 2020 [cited 2020 Dec 21]. Available from: [https://www.ukbiobank.ac.uk/media/s3af0k5q/ukb\\_serologystudy\\_month1\\_report.pdf](https://www.ukbiobank.ac.uk/media/s3af0k5q/ukb_serologystudy_month1_report.pdf)

121. Public Health England. Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report London: PHE; 2020 [Internet]. 2020 [cited 2020 Dec 21]. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/889981/Weekly\\_COVID19\\_Epidemiological\\_Summary\\_w23.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/889981/Weekly_COVID19_Epidemiological_Summary_w23.pdf)
122. Mulchandani R, Taylor-Phillips S, Jones H, Ades T, Borrow R, Linley E, et al. Self assessment overestimates historical COVID-19 disease relative to sensitive serological assays: cross sectional study in UK key workers. medRxiv [Internet]. 2020 Jan 1;2020.08.19.20178186. Available from: <http://medrxiv.org/content/early/2020/08/22/2020.08.19.20178186.abstract>
123. Nsn G, CJ, R M, P R, N L, Sn L, et al. High rates of SARS-CoV-2 seropositivity in nursing home residents. J Infect [Internet]. 2020 Aug; Available from: <https://europepmc.org/articles/PMC7449890>
124. Favara D, McAdam K, Cooke A, Bordessa-Kelly A, Budriunaite I, Bossingham S, et al. SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic [Internet]. medRxiv; 2020. Available from: <http://europepmc.org/abstract/PPR/PPR217237>
125. Ladhani S. Prospective active national surveillance of preschools and primary schools for SARS-CoV-2 infection and transmission in England, June 2020 (sKIDs COVID-19 surveillance in school KIDs) [Internet]. 2020 [cited 2020 Dec 21]. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/914700/sKIDs\\_Phase1Report\\_01sep2020.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/914700/sKIDs_Phase1Report_01sep2020.pdf)
126. Ward H, Atchison CJ, Whitaker M, Ainslie KEC, Elliott J, Okell LC, et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv [Internet]. 2020 Jan 1;2020.08.12.20173690. Available from: <http://medrxiv.org/content/early/2020/08/21/2020.08.12.20173690.abstract>
127. Delli  re S, Salmona M, Minier M, Gabassi A, Alanio A, Goff J Le, et al. Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech. J Clin Microbiol [Internet]. 2020 [cited 2021 Jan 1];58(8). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383543/>
128. Pegoraro M, Militello V, Salvagno GL, Gaino S, Bassi A, Caloi C, et al. Evaluation of three immunochromatographic tests in COVID-19 serologic diagnosis and their clinical usefulness. Eur J Clin Microbiol Infect Dis [Internet]. [cited 2021 Jan 1];1. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572234/>
129. BioWorld. Self-testing from home seen as a valid COVID-19 tracking method | 2020-08-17 | BioWorld [Internet]. [cited 2021 Jan 1]. Available from: <https://www.bioworld.com/articles/496767-self-testing-from-home-seen-as-a-valid-covid-19-tracking-method>
130. Mantelakis A, Spiers HVM, Lee CW, Chambers A, Joshi A. Availability of Personal Protective Equipment in NHS Hospitals During COVID-19: A National Survey. Ann Work Expo Heal [Internet]. [cited 2020 Dec 28]; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499547/>
131. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun [Internet]. 2020 Dec 9 [cited 2020 Dec 28];11(1):6317. Available from: <http://www.nature.com/articles/s41467-020-19741-6>



## PRISMA 2009 Flow Diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(7): e1000097. doi:10.1371/journal.pmed.1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).




Figure 2




Figure 3